RU2757329C1 - Method for therapy of cow catarral mastitis with complex preparation containing silver nanoparticles argovit and dimexide - Google Patents

Abstract

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to veterinary medicine, and for the treatment of catarrhal mastitis in cows. For this, a complex of preparations containing a 10% solution of argovit and a 5% solution of dimexide is injected intracisternally. The introduction is carried out in a dose of 10 ml 1 time in 24 hours for 3-4 days.

EFFECT: administration of a complex of drugs in the indicated concentrations and the mode of administration provides a reduction in the duration of treatment in the absence of an irritating effect on the breast tissue.

1 cl, 4 tbl, 3 ex

Description

The invention relates to the field of veterinary medicine, in particular, can be used in the treatment of catarrhal mastitis in cows.

Among most diseases of cows, mastitis occupies a special place, which is widespread and causes great economic damage to milk producers, processing industry enterprises and human health. Factors that reduce the resistance of the mammary gland and the body as a whole play an important role in the occurrence and spread of diseases of the mammary gland in cows, against which pathogenic microflora manifests its effect (Bogush A.A. Measure for the prevention, diagnosis and treatment of mastitis in cows / A. A. Bogush, V.E. Ivanov // Veterinary. - 2009. - No. 1. - P. 37; Vasiliev V.V. - S. 33-34).

If cows get sick with mastitis, their milk production decreases by 20-50%. The lifespan of animals is reduced from economically justified 5 lactations or more to 1-3, and also reduces the output of calves per 100 cows as a result of the death of newborns when drinking colostrum from sick mothers and infertility of animals. Thus, mastitis in cows is a big problem for commercial dairy farms and breeding stock (Parikov V.A.Effective domestic drugs for the prevention and treatment of mastitis in cows / V.A.Parikov, N.T. , D. M. Ponitkin, V. I. Mikhalev // Actual problems of diseases of the reproductive organs and mammary gland in animals. International scientific-practical conference. Voronezh, October 5-7, 2005. Mat.conf. - Voronezh: Europolygraphy , 2005 - S. 375-378).

In agricultural enterprises with industrial milk production technology, 31% of cows are ill with mastitis, with a clinical to subclinical mastitis ratio of 1: 2.3. Of the clinical forms of mastitis, catarrhal and purulent-catarrhal prevail, their share is 98% of the total number of sick cows (Filippova OV Unconventional methods of treating mastitis in cows. Diss. Candidate of Veterinary Sciences. Orenburg, 2000 - 122 p.) ...

Depending on the degree of influence of pathogenic factors and the state of resistance of the organism of cows, the process in the udder can lead to subclinical, and then clinical forms of the disease (catarrhal, etc.). Subclinical mastitis is characterized by a sluggish inflammatory process, in which the clinical signs of mastitis are very weak, or even do not appear at all. With catarrhal mastitis, the inflammatory process proceeds much more severely, since a large area of the udder parenchyma is affected with the degeneration of the glandular and integumentary epithelium and its subsequent rejection, sweating of exudate, emigration of leukocytes, mainly to the surface of the mucous membrane (Slobodyanik V.I. Immunological aspects of solving the problem of mastitis / VI Slobodyanik // Veterinary of agricultural animals. - 2010. - No. 10. - P. 20-28).

A known method of treating mastitis in cows using etiotropic agents. Antibiotics, sulfonamides, nitrofurans, and medicinal paints are used as etiotropic agents. The most common treatment for cows with mastitis is intracisternally injecting antimicrobials into the affected udder lobe. The frequency of administration of the drug and the course of treatment are regulated by the instructions for use.

The recovery of the animals is monitored 5-7 days after the completion of the course of treatment. In the absence of positive results, a repeated course of treatment with a drug to which the microflora isolated from the udder lobe affected by mastitis is sensitive (Slobodyanik V.I. T. Klimov [et al.] - Taganrog: Publishing Center Taganrog, State Pedagogical Institute, 2009. - 276 p.).

With this method of therapy, a number of negative effects arise, for example, milk with a residual amount of antibiotic substances cannot be taken to milk processing enterprises; microorganisms circulating in the economy develop resistance to the antibiotic drugs used, which means that their use in the case of treating other diseases will not be effective enough; the secondary toxic effect from the use of antibiotic drugs sometimes exceeds the primary therapeutic one; in modern conditions, the use of one antibiotic drug is often not effective enough and it is necessary to use two or more of their names at the same time; antibiotic drugs can cause drug allergies in animals and humans.

The closest solution adopted for the prototype is a drug for the treatment of cows with subclinical mastitis and the method of its use (application for the grant of a patent of the Russian Federation No. 2532407 dated November 10, 2014) by intracisternal administration of the drug, containing silver nanoparticles stabilized by submicron dioxide particles as active substances titanium, poly-N-vinylpyrrolidone-2, water obtained by electrochemical method. The drug is injected into the milk canal at a dose of 10 ml twice a day with an interval of 12 hours for 2-4 days.

The disadvantages of the method according to the prototype are: the high cost of the drug associated with the method of its manufacture, low therapeutic efficacy, due to the long period of treatment, is not used for the treatment of catarrhal mastitis in cows.

The problem solved by the claimed invention is to expand the arsenal of means and method of application, as well as to enhance the therapeutic effect of the used components of the drug.

The problem is solved by the fact that in the method of treating catal mastitis in cows, including the intracisternal administration of a complex antibacterial drug, where a complex of drugs argovit, Dimexide is used as an antibacterial drug in the form of 10% and 5% aqueous solutions at a dose of 10 ml once every 24 hours in within 3-4 days.

Argovit is a complex of highly dispersed particles of cluster silver, polyvinylpyrrolidone, and an aqueous solution obtained by the electric beam method. The drug has a wide spectrum of antimicrobial action against gram-positive and gram-negative, aerobic and anaerobic, spore-forming and asporogenic bacteria in the form of monocultures and microbial associations. Manufacturer LLC SPC "Vector Vita", Novosibirsk, e-mail: vectot-vita@ngs.ru.

Dimexide is a solution of the active substance dimethyl sulfoxide, which has pronounced anti-inflammatory,

analgesic and antiseptic properties. Producer of JSC Tatkhimfarmpreparaty, Kazan.

Example 1

The studies of the irritating effect of the preparation, a complex preparation containing argovit, dimexide in the form of 10% and 5% aqueous solutions, on the mammary gland of cows were carried out.

Fifteen clinically healthy black-and-white cows were selected on the basis of analogs. The drug was injected intracisternally into the left lobes of the udder at a dose of 10 ml per animal, the right lobes served as a control. After the administration of the drug argovit at 6, 12, 24, 48 and 72 hours, the state of the udder was taken into account, and milk samples were taken to count the number of somatic cells. When examining milk samples for the content of somatic cells, a slight increase was noted (by 10.1%) 6 hours after the drug was administered, and 48 hours after the drug was administered, the number of somatic cells decreased to 347.5 ± 17.1 thousand / ml and was within the physiological norm (Table 1).

Thus, a complex preparation containing argovit, dimexide in the form of 10% and 5% aqueous solutions does not irritate the mammary gland of cows and can be recommended for intracisternal administration.

Example 2

To determine the most optimal therapeutic dose of a preparation containing highly dispersed particles of cluster silver, obtained by the electrobeam method in combination with Dimexide, three groups of black-and-white cows with catarrhal mastitis were formed on the basis of analogs. The animals were injected with argovit in the form of 5%, 10% and 15% and dimexide in the form of 5% aqueous solutions intracisternally in doses of 5, 10, 15 ml 1 time in 24 hours.

The use of a complex preparation with a concentration of active substances (argovit 5% + 5% solution of Dimexidum) intracisternally in doses from 5 to 15 ml 1 time per 24 hours, showed the least therapeutic effect in the treatment of catarrhal mastitis in cows. Convalescence occurred on average on 4.5-4.6 days.

The use of a complex preparation with a concentration of active substances (argovit 10% + 5% solution of Dimexidum) intracisternally at a dose of 10 ml once every 24 hours showed the best therapeutic effect in the treatment of catarrhal mastitis in cows, in which recovery took place on 3.9 days.

The use of the drug with the concentration of the active substance (argovit 15% + 5% solution of Dimexidum) intracisternally in doses from 5 to 15 ml 1 time per 24 hours is characterized by similar indicators of the recovery time as the use of the drug (argovit 10% + 5% r -r Dimexide) at a dose of 10 ml (Table 2).

Example 3

Determination of the therapeutic efficacy of a complex preparation containing argovit, dimexide in the form of 10% and 5% aqueous solutions in the treatment of catarrhal mastitis in cows.

To study the comparative efficacy of therapy for catarrhal mastitis in cows, three groups of animals were formed according to the analogous principle: the first group (n = 20) was injected with dienomast (contains: 8.75 mg of dioxidine, 17.5 mg of gentamicin sulfate, 43.75 mg of wax bee) intracisternally 10 ml, 1 time per day; the second group (n = 20) was injected with a preparation containing silver nanoparticles stabilized by submicron particles of titanium dioxide, poly-N-vinylpyrrolidone-2, water obtained by the electrochemical method (argomast) intracisternally at a dose of 15 ml, 2 times a day; the third group (n = 20) was injected intracisternally with a complex preparation containing argovit, dimexide in the form of 10% and 5% aqueous solutions at a dose of 10 ml 1 time in 24 hours for 3-4 days.

The therapeutic efficacy of a complex preparation containing argovit, dimexide in the form of 10% and 5% aqueous solutions was determined by the number of days of treatment, the period of which was established by a negative dimastin test. Also, somatic cells were counted daily in the Goryaev counting chamber, where the indicator of recovery was their presence in an amount of less than 400 thousand cells / ml of milk. By the time of recovery, the local temperature of the lobes of the mammary glands undergoing treatment was within the physiological norm, the skin of the udder was elastic and painless (Table 3).

In the course of treatment, in samples of udder secretions from cows in the experimental and control groups, there was a decrease in the content of somatic cells in catarrhal mastitis - by 69.6; 71.85 and 78.8%, respectively.

The average duration of treatment of catarrhal mastitis in cows with dienomast was 6.9 ± 0.4 days. Moreover, milk from these cows was utilized during treatment and within 7 days after the last use of the drug, according to the instructions for use of the drug (Table 4).

Thus, the total period for culling milk from cows with catarrhal mastitis (dienomast) was 13.9 days, while when treating the same mastitis with argomast and a complex preparation containing argovit, dimexide in the form of 10% and 5% aqueous solutions the average period the rejection rate was 6.2 and 3.9 days, respectively.

Thus, the proposed method for the treatment of catarrhal mastitis in cows with a complex preparation containing argovit, dimexide in the form of 10% and 5% aqueous solutions when administered intracisternally at a dose of 10 ml 1 time in 24 hours for 3-4 days is more acceptable in comparison with other methods of treatment (dienomast and argomast), which was expressed in a decrease in the duration of therapy and a decrease in somatic cells in milk.

In this regard, the proposed method for the treatment of catarrhal mastitis in cows with a complex preparation containing argovit, dimexide in the form of 10% and 5% aqueous solutions when administered intracisternally at a dose of 10 ml 1 time in 24 hours for 3-4 days contributes to the improvement of therapeutic measures, accompanied by a 1.6-1.77-fold reduction in the treatment time for cow mastitis.

Claims (1)

A method of treating catarrhal mastitis in cows with a complex preparation containing silver nanoparticles argovit and dimethyl sulfoxide, including intracisternal administration of a complex antibacterial preparation, where a complex of preparations argovit, dimexide in the form of 10% and 5% aqueous solutions in a dose of 10 ml is used as an antibacterial preparation 1 time in 24 hours for 3-4 days.